Daniel E. Madsen

Ballerup, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial.

Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial.

Journal: Dermatology and therapy
Published: January 07, 2026

Reply to 'Delayed absorption and systemic variability of topical delgocitinib in Chronic Hand Eczema'.

Reply to 'Delayed absorption and systemic variability of topical delgocitinib in Chronic Hand Eczema'.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 17, 2025

Epidermal Penetration of Tape-Stripping Differs Between Palmar and Dorsal Hand Skin: Implications for Biomarker Assessment in Chronic Hand Eczema.

Epidermal Penetration of Tape-Stripping Differs Between Palmar and Dorsal Hand Skin: Implications for Biomarker Assessment in Chronic Hand Eczema.

Journal: Contact dermatitis
Published: February 25, 2025

Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema.

Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: February 06, 2025

Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment.

Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment.

Journal: American journal of clinical dermatology
Published: December 02, 2024

Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.

Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.

Journal: Allergy
Published: September 06, 2023

A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice.

A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice.

Journal: Blood
Published: December 10, 2020

Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test - Demonstrated in vitro and ex vivo.

Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test - Demonstrated in vitro and ex vivo.

Journal: PloS one
Published: September 19, 2016

C1-inhibitor polymers activate the FXII-dependent kallikrein-kinin system: Implication for a role in hereditary angioedema.

C1-inhibitor polymers activate the FXII-dependent kallikrein-kinin system: Implication for a role in hereditary angioedema.

Journal: Biochimica et biophysica acta
Published: October 17, 2014

Presence of C1-inhibitor polymers in a subset of patients suffering from hereditary angioedema.

Presence of C1-inhibitor polymers in a subset of patients suffering from hereditary angioedema.

Journal: PloS one
Published: July 30, 2014

Three months of strictly controlled daily endurance exercise reduces thrombin generation and fibrinolytic risk markers in younger moderately overweight men.

Three months of strictly controlled daily endurance exercise reduces thrombin generation and fibrinolytic risk markers in younger moderately overweight men.

Journal: European journal of applied physiology
Published: July 16, 2014

ELISA for determination of total coagulation factor XII concentration in human plasma.

ELISA for determination of total coagulation factor XII concentration in human plasma.

Journal: Journal of immunological methods
Published: October 23, 2012
Showing 1-12 of 13

Last Updated: 09/26/2026